Carr, Rosalie A.Kiel, Brandon A.Roch, Alexandra M.Ceppa, Eugene P.House, Michael G.Zyromski, Nicholas J.Nakeeb, AttilaSchmidt, C. Max2017-12-222017-12-222017Carr, R. A., Kiel, B. A., Roch, A. M., Ceppa, E. P., House, M. G., Zyromski, N. J., … Schmidt, C. M. (2017). Cancer history: A predictor of IPMN subtype and dysplastic status? The American Journal of Surgery. https://doi.org/10.1016/j.amjsurg.2017.11.014https://hdl.handle.net/1805/14900Introduction The aim of this study was to determine the association of PMH and FH of pancreatic (PDAC) and non-pancreatic cancers with IPMN malignant risk. Methods A retrospective review of a prospective database of IPMN patients undergoing resection was performed to assess FH and PMH. Results FH of PDAC was present in 13% of 362 included patients. Of these, 8% had at least one first degree relative (FDR) with PDAC. The rate of PDAC positive FH in non-invasive versus invasive IPMN patients was 14% and 8%, respectively (p = 0.3). In main duct IPMN patients, FH (44%) and PMH of non-pancreatic cancer (16%) was higher than that seen in branch duct IPMN (FH 29%; PMH 6%; p = 0.004 and 0.008). Conclusions FH of PDAC is not associated with IPMN malignant progression. FH and PMH of non-pancreatic cancer is associated with main duct IPMN, the subtype with the highest rate of invasive transformation.enPublisher PolicyIPMNfamily historypancreatic ductal adenocarcinomaArticle